Advanced Search

    Technical Analysis for GNTA - Genenta Science S.p.A.

    Grade Last Price % Change Price Change
    B 6.00 -3.21% -0.20
    GNTA closed down 3.21 percent on Wednesday, March 22, 2023, on 1.77 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical GNTA trend table...
    Date Alert Name Type % Chg
    50 DMA Resistance Bearish 0.00%
    MACD Bearish Centerline Cross Bearish 0.00%
    200 DMA Support Bullish 0.00%
    Doji - Bullish? Reversal 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Stochastic Reached Oversold Weakness 0.00%
    Strong but Oversold Other 0.00%
    BB Squeeze Ended Range Expansion 0.00%
    Outside Day Range Expansion 0.00%
    Strong, Oversold and Reversal Signs Reversal 0.00%
    Older End-of-Day Signals for GNTA ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    Rose Above Lower Bollinger Band 1 day ago
    Fell Below 50 DMA 3 days ago
    50 DMA Support 3 days ago
    Down 5% 3 days ago
    Down 3% 3 days ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators Basic chart:

    Profile

    • Earnings date: Unknown
    Genenta is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). TemferonTM, which is under investigation in a Phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenges in immuno-oncology.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Biology Solid Tumors Oncology Cancer Immunotherapy Gene Therapy Cell Biology Glioblastoma Platform Technology Brain Tumor Solid Tumor Cancers Glioblastoma Multiforme

    Is GNTA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Mar 2 Genenta's brain cancer cell therapy gets FDA orphan drug status
    Mar 2 FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme
    Feb 7 Genenta expands pact with AGC Biologics to make cell therapy products for trials
    Feb 7 Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement
    Jan 29 We Think Genenta Science (NASDAQ:GNTA) Can Easily Afford To Drive Business Growth
    Dec 8 Genenta Science S.p.A. (NASDAQ:GNTA) most popular amongst individual investors who own 60%, insiders hold 29%
    Nov 7 Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients
    Oct 24 Genenta Science  GAAP EPS of €0.27 beats by €0.42
    Oct 24 Genenta Provides First Half 2022 Business Update and Financial Results
    Oct 17 10 Best Italian Stocks To Buy Now
    See more GNTA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 9.33
    52 Week Low 3.9
    Average Volume 3,285
    200-Day Moving Average 5.93
    50-Day Moving Average 6.40
    20-Day Moving Average 6.59
    10-Day Moving Average 6.57
    Average True Range 0.38
    RSI 38.27
    ADX 21.5
    +DI 21.10
    -DI 20.56
    Chandelier Exit (Long, 3 ATRs) 5.94
    Chandelier Exit (Short, 3 ATRs) 6.94
    Upper Bollinger Bands 7.10
    Lower Bollinger Band 6.09
    Percent B (%b) -0.08
    BandWidth 15.36
    MACD Line -0.03
    MACD Signal Line 0.08
    MACD Histogram -0.1036
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.11
    Resistance 3 (R3) 7.17 6.85 6.93
    Resistance 2 (R2) 6.85 6.57 6.83 6.86
    Resistance 1 (R1) 6.43 6.40 6.27 6.37 6.80
    Pivot Point 6.11 6.11 6.04 6.09 6.11
    Support 1 (S1) 5.69 5.83 5.53 5.63 5.20
    Support 2 (S2) 5.37 5.66 5.35 5.14
    Support 3 (S3) 4.95 5.37 5.08
    Support 4 (S4) 4.89